Ryaltris, which was developed by Glenmark, is a novel, fixed-dose combination nasal spray of an anti-histamine (olopatadine hydrochloride) and a steroid (mometasone furoate). Each unit of the ...

approval for nasal spray fixed dose prescription drug for seasonal allergic rhinitis Ryaltris. According to Glenmark, the drug is for rhinitis in adults and paediatric patients 12 years of age and ...

The first recall affects 45,504 bottles of Ryaltris (olopatadine hydrochloride and mometasone furoate) Nasal Spray. Glenmark ...

(RTTNews) - Glenmark Pharmaceuticals Inc., USA announced that it has received final approval from the U.S. Food & Drug Administration (FDA) for its Olopatadine Hydrochloride Ophthalmic Solution ...